Advertisement

Current Cardiology Reports

, 17:93 | Cite as

Is It Daily, Monthly, or Yearly Blood Pressure Variability that Enhances Cardiovascular Risk?

  • Eamon Dolan
  • Eoin O’Brien
Hypertension (WB White and AJ Peixoto, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Hypertension

Abstract

Variability is a phenomenon common to most biological processes that we can measure and is a particular feature of blood pressure (BP). Variability causes concern for many physicians regarding its clinical meaning and potential impact on cardiovascular risk. In this review, we assess the role of different time periods of blood pressure variability (BPV) in cardiovascular risk stratification. We review the indices of BPV derived from ambulatory blood pressure measurement (ABPM), home blood pressure measurement (HBPM), or at the clinic setting with the intention of providing a clear message for clinical practice. BPV, either derived from ABPM or HBPM, does not consistently augment cardiovascular risk prediction over and beyond that of average BP, particularly in low-risk individuals. That said, it would seem that certain medications such as calcium channel blockers may have a beneficial effect on visit-to-visit BPV and perhaps reduce the associated cardiovascular risk. This highlights the benefits in using combination therapy which might couple a number of therapeutic benefits such as the reductions of mean blood pressure and BPV. Overall, we should remain aware that the average BP level remains the main modifiable risk factor derived from BP measurements and continue to improve the control of hypertension and adverse health outcomes.

Keywords

Hypertension Blood pressure variability Stroke Cardiovascular risk 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Eamon Dolan and Eoin O’Brien declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11–9.CrossRefPubMedGoogle Scholar
  2. 2.••
    Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2224–60. This publication highlights the important role hypertension plays in global disease development. CrossRefGoogle Scholar
  3. 3.
    Perkovic V, Huxley R, Wu Y, et al. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension. 2007;50:991–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Turner JR, O’Brien E. Diagnosis and treatment of resistant hypertension: the critical role of ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2013;15(12):868–73.CrossRefGoogle Scholar
  5. 5.
    Campbell NR, Sheldon T. The Canadian effort to prevent and control hypertension: can other countries adopt Canadian strategies? Curr Opin Cardiol. 2010;25:366–72.CrossRefPubMedGoogle Scholar
  6. 6.
    O’Brien E, Dolan E, Atkins N. Failure to provide ABPM to All hypertensive patients amounts to medical ineptitude. J Clin Hypertens (Greenwich). 2015;17(6):462–5.CrossRefGoogle Scholar
  7. 7.
    Parati G, Ochoa JE, Lombardi C, et al. Blood pressure variability: assessment, predictive value, and potential as a therapeutic target. Curr Hypertens Rep. 2015;17(4):537.CrossRefPubMedGoogle Scholar
  8. 8.
    Dahlöf B, Sever PS, Poulter NR, ASCOT Investigators, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.CrossRefPubMedGoogle Scholar
  9. 9.
    Poulter NR, Wedel H, Dahlöf B, ASCOT Investigators, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366(9489):907–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Williams B, Williams B, Lacy PS, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–25.CrossRefPubMedGoogle Scholar
  11. 11.
    Dolan E, Stanton AV, Thom S, ASCOT Investigators, et al. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients—an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens. 2009;27(4):876–85.CrossRefPubMedGoogle Scholar
  12. 12.
    Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375(9718):895–905.CrossRefPubMedGoogle Scholar
  13. 13.••
    Parati G, Ochoa JE, Lombardi C, et al. Assessment and management of blood-pressure variability. Nat Rev Cardiol. 2013;10:143–55. An excellent review of this topic by a group who have done much to advance our awareness of the importance of BPV. CrossRefPubMedGoogle Scholar
  14. 14.
    Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375(9718):938–48.CrossRefPubMedGoogle Scholar
  15. 15.
    Mena L, Pintos S, Queipo NV, et al. A reliable index for the prognostic significance of blood pressure variability. J Hypertens. 2005;23(3):505–11.CrossRefPubMedGoogle Scholar
  16. 16.
    Bilo G, Giglio A, Styczkiewicz K, et al. A new method for assessing 24-h blood pressure variability after excluding the contribution of nocturnal blood pressure fall. J Hypertens. 2007;25(10):2058–66.CrossRefPubMedGoogle Scholar
  17. 17.
    Mancia G, Bombelli M, Facchetti R, et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension. 2007;49(6):1265–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Stolarz-Skrzypek K, Thijs L, et al. Blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome. Hypertens Res. 2010;33(8):757–66.CrossRefPubMedGoogle Scholar
  19. 19.
    Hansen TW, Thijs L, Li Y, Boggia J, et al. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension. 2010;55(4):1049–57.CrossRefPubMedGoogle Scholar
  20. 20.
    Stolarz-Skrzypek K, Thijs L, et al. Short-term blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO). Acta Cardiol. 2011;66(6):701–6.PubMedGoogle Scholar
  21. 21.••
    Zhang Y, Agnoletti D, Safar ME, et al. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension. 2011;58(2):155–60. This manuscript describes the potential reduction of BPV by certain antihypertensive medications. CrossRefPubMedGoogle Scholar
  22. 22.
    Levi-Marpillat N, Macquin-Mavier I, et al. Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension. Hypertens Res. 2014;37(6):585–90.CrossRefPubMedGoogle Scholar
  23. 23.
    Matsui Y, Ishikawa J, Eguchi K, et al. Maximum value of home blood pressure: a novel indicator of target organ damage in hypertension. Hypertension. 2011;57(6):1087–93.CrossRefPubMedGoogle Scholar
  24. 24.
    Ushigome E, Fukui M, Hamaguchi M, et al. The coefficient variation of home blood pressure is a novel factor associated with macroalbuminuria in type 2 diabetes mellitus. Hypertens Res. 2011;34(12):1271–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Hashimoto T, Kikuya M, Ohkubo T, et al. Home blood pressure level, blood pressure variability, smoking, and stroke risk in Japanese men: the Ohasama study. Am J Hypertens. 2012;25(8):883–91.CrossRefPubMedGoogle Scholar
  26. 26.
    Johansson JK, Niiranen TJ, Puukka PJ, et al. Prognostic value of the variability in home-measured blood pressure and heart rate: the Finn-Home Study. Hypertension. 2012;59(2):212–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Schutte R, Thijs L, Liu YP, et al. Within-subject blood pressure level—not variability—predicts fatal and nonfatal outcomes in a general population. Hypertension. 2012;60(5):1138–47.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9(5):469–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Yokota K, Fukuda M, Matsui Y, et al. Impact of visit-to-visit variability of blood pressure on deterioration of renal function in patients with non-diabetic chronic kidney disease. Hypertens Res. 2013;36:151–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Diaz KM, Veerabhadrappa P, Kashem MA, et al. Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African Americans. Hypertens Res : Off J Jpn Soc Hypertens. 2012;35(1):55–61.CrossRefGoogle Scholar
  31. 31.
    Nagai M, Hoshide S, Ishikawa J, et al. Visit-to visit blood pressure variations: new independent determinants for cognitive function in the elderly at high risk of cardiovascular disease. J Hypertens. 2012;30(8):1556–63.CrossRefPubMedGoogle Scholar
  32. 32.
    Muntner P, Shimbo D, Tonelli M, et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57(2):160–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Shimbo D, Newman JD, Aragaki AK, et al. Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women’s Health Initiative. Hypertension. 2012;60(3):625–30.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Mancia G, Facchetti R, Parati G, et al. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012;30(6):1241–51.CrossRefPubMedGoogle Scholar
  35. 35.
    Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007;50(2):299–305.CrossRefPubMedGoogle Scholar
  36. 36.
    O’Brien E, Sheridan J, O’Malley K. Dippers and non-dippers. Lancet. 1988;2(8607):397.CrossRefPubMedGoogle Scholar
  37. 37.
    Cuspidi C, Sala C, Tadic M, et al. Non-dipping pattern and subclinical cardiac damage in untreated hypertension: a systematic review and meta-analysis of echocardiographic studies. Am J Hypertens. 2015;24.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Stroke and Hypertension UnitConnolly HospitalDublinIreland
  2. 2.Conway InstituteUniversity College DublinDublinIreland

Personalised recommendations